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OBJECTIVES: Bioactive Carmeda® heparin-coated extracorporeal circuits (ECCs)
have been shown to reduce contact phase and coagulation activation during
cardiopulmonary bypass (CPB). Heparin coating is therefore effective in safely
reducing coagulation during routine CPB. Balance® Biosurface is a new, recently
developed biopassive coating containing negatively charged sulphonated
polymers. This study sought to compare the clotting activation and
thromboresistance of the Balance® (B) circuit with that of the Carmeda® (C) with
full-dose systemic heparin (FDH) and reduced-dose systemic heparin (RDH).
METHODS: This ex vivo study set-up comprising 40 experiments consisted of
simplified ECC and circulation of freshly donated human blood. RDH and FDH
regimens were obtained with 0.5 IU/ml and 1 IU/ml heparin administered to reach
target activated clotting times (ACTs) of 250 and 500 s, respectively. The study
design comprised four groups: FDH-C, FDH-B, RDH-C and RDH-B (all n = 10).
Blood was sampled prior to and during the 2-h CPB. Coagulation activation was
assessed (FXIIa, F1.2) and electron microscope scan imaging of oxygenators
enabled determination of adhesion scores.
RESULTS: With a biopassive compared with bioactive surface, mean ACT was
lower, regardless of the heparin regimen applied (P < 0.001), whereas the total
heparin dose required to maintain ACT was above target level (P < 0.001).
However, FXIIa and F1.2 values were similar in all groups throughout, as were
pressure gradients among oxygenators. All groups demonstrated similar adhesion
scores following ultrastructural oxygenator assessment.
CONCLUSIONS: In the absence of surgical-related haemostatic disturbances and
based on target ACT levels under reduced- or full-dose heparin, the clotting
process was similar to heparin-coated and new sulphonated polymer-coated ECC,
both demonstrating similar thromboresistance.
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